Lumosa Therapeutics Co., Ltd. (TPEX:6535)
Taiwan · Delayed Price · Currency is TWD 115.00
-0.50 (-0.43%)
Jun 5, 2026, 1:30 PM CST
Lumosa Therapeutics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 31.42 | 35.83 | 39.15 | 56.92 | 26.64 | 17.36 | |
Revenue Growth (YoY) | -27.92% | -8.49% | -31.21% | 113.63% | 53.45% | -19.81% |
Cost of Revenue | 12.92 | 13.96 | 21.44 | 15.44 | 12.08 | 7.47 |
Gross Profit | 18.5 | 21.87 | 17.71 | 41.48 | 14.56 | 9.89 |
Selling, General & Admin | 51.07 | 51.01 | 51.8 | 47.8 | 40.02 | 34.12 |
Research & Development | 261 | 304.37 | 322.86 | 369.3 | 280.46 | 406.05 |
Operating Expenses | 312.06 | 355.36 | 374.83 | 417.26 | 320.48 | 440.17 |
Operating Income | -293.56 | -333.49 | -357.12 | -375.78 | -305.92 | -430.28 |
Interest Expense | -0.17 | -0.2 | -0.19 | -0.05 | -0.15 | -0.26 |
Interest & Investment Income | 18.24 | 20.16 | 13.43 | 18.49 | 5.84 | 3.46 |
Currency Exchange Gain (Loss) | 0.57 | 0.29 | 6.87 | -4.21 | 11.02 | -3.73 |
Other Non Operating Income (Expenses) | 6.79 | 6.91 | 2.41 | 2.76 | 2.11 | 1.67 |
EBT Excluding Unusual Items | -268.13 | -306.32 | -334.6 | -358.79 | -287.1 | -429.14 |
Impairment of Goodwill | - | - | - | - | - | -78.49 |
Gain (Loss) on Sale of Investments | -93.82 | -40.29 | -102.24 | 119.08 | -217.4 | 627.61 |
Asset Writedown | - | - | - | -10.37 | - | -24.03 |
Other Unusual Items | - | - | - | - | 0.05 | - |
Pretax Income | -361.95 | -346.62 | -436.84 | -250.09 | -504.45 | 95.95 |
Income Tax Expense | - | - | - | 0.25 | 0.04 | - |
Earnings From Continuing Operations | -361.95 | -346.62 | -436.84 | -250.33 | -504.48 | 95.95 |
Minority Interest in Earnings | 5.91 | 6.08 | 12.05 | 12.29 | 9.82 | - |
Net Income | -356.04 | -340.54 | -424.78 | -238.04 | -494.66 | 95.95 |
Net Income to Common | -356.04 | -340.54 | -424.78 | -238.04 | -494.66 | 95.95 |
Shares Outstanding (Basic) | 166 | 166 | 163 | 162 | 162 | 151 |
Shares Outstanding (Diluted) | 166 | 166 | 163 | 162 | 162 | 151 |
Shares Change (YoY) | 1.01% | 1.68% | 0.64% | 0.03% | 7.61% | 24.92% |
EPS (Basic) | -2.14 | -2.05 | -2.60 | -1.47 | -3.05 | 0.64 |
EPS (Diluted) | -2.14 | -2.05 | -2.60 | -1.47 | -3.05 | 0.64 |
Free Cash Flow | -331.98 | -361.16 | -296.78 | -342.53 | -302.74 | -452.69 |
Free Cash Flow Per Share | -2.00 | -2.17 | -1.81 | -2.11 | -1.86 | -3.00 |
Gross Margin | 58.89% | 61.05% | 45.24% | 72.88% | 54.65% | 56.96% |
Operating Margin | -934.37% | -930.73% | -912.09% | -660.23% | -1148.26% | -2478.27% |
Profit Margin | -1133.24% | -950.41% | -1084.91% | -418.23% | -1856.70% | 552.62% |
Free Cash Flow Margin | -1056.65% | -1007.96% | -757.97% | -601.82% | -1136.33% | -2607.34% |
EBITDA | -289.27 | -329.17 | -353.03 | -356.93 | -288.66 | -403.81 |
D&A For EBITDA | 4.29 | 4.32 | 4.09 | 18.85 | 17.26 | 26.47 |
EBIT | -293.56 | -333.49 | -357.12 | -375.78 | -305.92 | -430.28 |